The liquid biopsy field can also exploit the smaller MassARRAY format. Genetic testing on a MassARRAY system can cost less than a tenth of the cost of next-generation sequencing tests. The MassARRAY platform's assay design software and services allow clinical laboratories to develop targeted, actionable panels for routine or specialized tests. Due to the confidence level that mass spectrometry provides, MassARRAY data are often used to validate variants detected from genome sequencing in the research and clinical settings. The MassARRAY system detects genetic variation directly by label-free mass spectrometry, analyzing up to 50 genetic loci per well. The 24-well scale is also ideal for clinical research studies, which often involve targeted testing of a small cohort of 5 to 50 patients," said Dansky. "With the new 24-well system labs can cut wait times and costs for smaller panels or panels that are run less often, such as a lung cancer panel for ALK and other gene mutations. With our powerful, proven MassARRAY technology, we are working towards enabling clinical laboratories to translate precision medicine into widespread use." "While the research community explores the potential hidden in the human genome, clinicians can utilize validated biomarkers to guide the best outcome for their patients. We're answering those sentiments with a flexible platform that drives down costs to a few dollars to tens of dollars per sample and cuts out big bioinformatics," said Dansky. "Labs repeatedly told us if various platforms afforded greater freedom-in terms of test development, accurate results at low cost, and turnaround times-they could be providing more genetic tests to more patients.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |